论文部分内容阅读
目的呼吸兴奋剂联合无创Bi PAP治疗慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭的临床疗效。方法选择徐州市贾汪区汴塘镇中心卫生院2013年5月—2015年5月收治的60例COPD合并Ⅱ型呼吸衰竭患者,根据数字随机分配的原则将患者分为治疗组30例与对照组30例。对照组患者给予常规治疗方案,静脉滴注尼可刹米注射液,治疗组患者在对照组治疗的基础上加用无创Bi PAP,比较两组患者的Pa O2及Pa CO2水平、临床疗效及不良反应发生情况。结果治疗组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者Pa O2、Pa CO2比较,差异无统计学意义(P>0.05);治疗后治疗组患者的Pa O2高于对照组,Pa CO2低于对照组,差异有统计学意义(P<0.05)。治疗组患者不良反应/并发症发生率低于对照组,差异有统计学意义(P<0.05)。结论呼吸兴奋剂联合无创Bi PAP治疗COPD合并Ⅱ型呼吸衰竭可有效改善患者Pa O2及Pa CO2水平,具有较好的临床疗效,且不良反应/并发症发生率低,安全性高。
Objective To investigate the clinical effect of non-invasive Bi PAP combined with respiratory stimulant in the treatment of chronic obstructive pulmonary disease (COPD) complicated with respiratory failure. Methods Sixty COPD patients with type Ⅱ respiratory failure who were treated in Qiantang Central Hospital, Jiawang District, Xuzhou City from May 2013 to May 2015 were divided into treatment group (30 cases) and control group according to the principle of random number distribution Group of 30 cases. Patients in the control group were given routine treatment and intravenous injection of niccaseimide. The patients in the treatment group were given non-invasive Bi PAP on the basis of the control group. PaO2 and Pa CO2 levels were compared between the two groups. The clinical efficacy and adverse effects Reaction occurred. Results The total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P <0.05). There was no significant difference in PaO 2 and PaCO 2 between the two groups before treatment (P> 0.05). After treatment, the PaO 2 in the treatment group was higher than that in the control group, PaCO 2 was lower than that in the control group (P <0.05). The incidence of adverse reactions / complication in the treatment group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusions Respiratory stimulant combined with noninvasive Bi PAP can effectively improve PaO2 and Pa CO2 levels in COPD patients with type Ⅱ respiratory failure. It has good clinical efficacy and low incidence of adverse reactions / complications and high safety.